A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
Immune checkpoint inhibitors (ICIs) have been incorporated into various clinical oncology guidelines for systemic treatment of advanced non-small cell lung cancers (aNSCLC). However, less than 50% (and 20%) of...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Kristin L. Ayers, Meng Ma, Gaspard Debussche, David Corrigan, Jonathan McCafferty, Kyeryoung Lee, Scott Newman, Xiang Zhou, Fred R. Hirsch, Philip C. Mack, Jane J. Liu, Eric E. Schadt, Rong Chen and Shuyu D. Li Tags: Research Source Type: research